Up to 75% of results from prostate biopsies performed in the US are negative for high-grade disease. IsoPSA can help reduce unnecessary prostate biopsies by up to 55%.¹
IsoPSA is included in NCCN® Prostate Cancer Early Detection Guidelines.
Prostate cancer can cause PSA levels to increase, but so can benign factors such as enlargement of the prostate, infections, sexual activity–even undergoing a prostate exam. IsoPSA is an additional test for men that helps determine whether cancer may be the cause of their elevated PSA levels.
Unlike the PSA test, which measures the total amount of PSA protein circulating in the blood, IsoPSA can help identify certain types of PSA proteins that were made by cancer cells. This insight provides greater clarity for ruling out risk of high-grade, aggressive cancer and the need for a prostate biopsy.
IsoPSA is indicated for men over 50 who have elevated PSA levels (>4ng/mL).
Alpha blockers and 5α-reductase inhibitors commonly prescribed for benign prostate hyperplasia (BPH) don’t interfere with IsoPSA results.
1. Scovell J, et al., Urol. Pract 2022
CONTRAINDICATIONS:
IsoPSA is not indicated for men under 50 years of age, men who have had a recent (<72 hours) prostate manipulation, including DRE; recent (<2 weeks) UTI and/or prostatitis; recent (<30 days) prostate surgery, urinary catheterization, prostate infarction, or endoscopic evaluation; or diagnosis of prostate cancer or other urinary tract malignancy.
